Morepen Laboratories Limited has informed the Exchange regarding Appointment of Vijender Sharma & Co., Cost Auditors as Other of the company w.e.f. April 01, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories' board, at its May 12, 2025 meeting, approved audited consolidated FY25 results showing total income of Rs. 1,829.94 crores (up 7.4% YoY) and net profit after minority interest of Rs. 118.02 crores (up 22.7% YoY), with FY25 EPS at Rs. 2.20 vs Rs. 1.88 in FY24. A final dividend of Rs. 0.20 per equity share (face value Rs. 2) was recommended for FY25, subject to shareholder approval. The board executed an addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the 'appointed date' for the medical devices hive-off from February 1, 2025 to April 1, 2025. It also approved the incorporation of a Wholly Owned Subsidiary in Dubai, UAE, through Morepen Medipath to expand B2C and B2B medical device segments. Additionally, M/s. Vijender Sharma & Co. were appointed as Cost Auditors for FY26 and M/s. Harvinder & Associates as Internal Auditors for FY25-26, both on the Audit Committee's recommendation. The statutory auditor S.P. Babuta & Associates issued an unmodified opinion on the results.
Strong double-digit profit growth and a continued dividend signal solid operational health, while the medical devices restructuring and Dubai WOS lay the groundwork for expansion into higher-margin, global markets — likely to be viewed positively by investors.